{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:15:02Z","timestamp":1771640102926,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009182","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,4,6]],"date-time":"2014-04-06T00:00:00Z","timestamp":1396742400000}}],"reference-count":138,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009182.pub2","type":"journal-article","created":{"date-parts":[[2014,4,6]],"date-time":"2014-04-06T08:50:01Z","timestamp":1396774201000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Nitazoxanide for chronic hepatitis C"],"prefix":"10.1002","volume":"2014","author":[{"given":"Kristiana","family":"Nikolova","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Grevstad","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812; Blegdamsvej 9 Dept 78.22 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus C","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,6]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1053\/j.gastro.2010.05.067","article-title":"A phase II, randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in naive patients with chronic hepatitis C genotype 1 infection: final report","volume":"139","author":"Bacon","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0002|cit2","first-page":"S3","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virological response rate","volume":"52","author":"Bacon","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1016\/S0168-8278(09)61051-5","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR","volume":"50","author":"Bacon","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0004|cit4","unstructured":"Berrie C Combined thiazolide nitazoxanide plus PEG-IFN Alfa-2a\/ribavirin improved viral response in HCV genotype 1: presented at EASL 2010 http:\/\/www.firstwordpharma.com\/node\/604408?tsid=17#axzz2y2MTgiDa"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0005|cit5","unstructured":"NCT00637923 Study of nitazoxanide, peginterferon alfa-2a and ribavirin in treatment-naive hepatitis C patients (STEALTH-3) http:\/\/clinicaltrials.gov\/show\/NCT00637923"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Basu P Nair T Farhat S Ang L Jafri M Mittimani K Pegylated interferon alfa, nitazoxanide, telapravir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients-a randomized placebo control clinical pilot trial (INTRIGUE C) interim Hepatology International 2012 64","DOI":"10.14309\/00000434-201210001-00363"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Basu P Nair T Farhat S Ang L Mittimani K Shah NJ Peg-interferon alfa, nitazoxanide, telapravir, ribaverin, in genotype 1 in treatment experienced chronic hepatitis C patients - a randomized control pilot trial Journal of Gastroenterology and Hepatology 2012 207","DOI":"10.14309\/00000434-201210001-00363"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Basu P Shah N Farhat S Siriki R Rahman M Lynn A Pegylated interferon alfa, nitazoxanide, telaprevir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients - a randomized placebo control clinical pilot trial (intrigue-C) American Journal of Gastroenterology 2012 S154","DOI":"10.14309\/00000434-201210001-00363"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Basu P Shah N Farhat S Siriki R Rahman MD Lynn A Pegylated interferon alfa, nitazoxanide, telaprevir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients - a randomized placebo control clinical pilot trial (INTRIGUE-C) Interim American Journal of Gastroenterology 2012 S932","DOI":"10.1016\/S0016-5085(12)63615-4"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0010|cit10","unstructured":"Keeffe EB Elfert A Abousaif S Rossignol J Controlled release nitazoxanide in combination with peginterferon alfa-2a plus ribavirin results in high early virologic response rates for treatment of chronic hepatitis C genotype 4 Hepatology 2009 1038A"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/S0168-8278(11)61216-6","article-title":"Dose-related increase in virologic responses using controlled release nitazoxanide plus peginterferon alfa-2A and ribavirin for treatment of chronic hepatitis C genotype 4: final report","volume":"54","author":"Keeffe","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0012|cit12","first-page":"251","article-title":"A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4","volume":"41","author":"Kabil","year":"2011","journal-title":"Journal of the Egyptian Society of Parasitology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Rossignol JF Kabil SM El-Gohary Y Keeffe EB Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4 Alimentary Pharmacology & Therapeutics 2008 574 80","DOI":"10.1111\/j.1365-2036.2008.03781.x"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009182.pub2-BIB0014|cit14","first-page":"S311\u20132","article-title":"Randomized double blind placebo-controlled trial of nitazoxanide in the treatment of patients with chronic hepatitis C genotype 4 [abstract]","volume":"48","author":"Rossignol","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD009182.pub2-BIB0016|cit15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009182.pub2-BIB0017|cit16","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(08)60070-7","article-title":"Randomized controlled trial of nitazoxanide-peginterferonribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4","volume":"48","author":"Rossignol","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0015|cit17","first-page":"316A","article-title":"Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4","volume":"46","author":"Rossignol","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0018|cit18","unstructured":"NCT01276756 Efficacy of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01276756?term=Efficacy+of+nitazoxanide+in+the+treatment+of+chronic+hepatitis+C+virus+%28HCV%29&rank=1"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0019|cit19","unstructured":"Shehab H [pers comm] Efficiacy of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) By email"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Shehab H Elbaz T Draz D The addition of nitazoxanide to pegylated interferon and ribavirin does not improve SVR rates in chronic HCV genotype 4 Journal of Hepatology 2013 495","DOI":"10.1016\/S0168-8278(13)61219-2"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0021|cit21","unstructured":"NCT00495391 Study of nitazoxanide, peginterferon alfa-2a and ribavirin for the treatment of hepatitis c (STEALTH-2) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00495391?term=NCT00495391&rank=1"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Shiffman M Ahmed A Jacobson I Pruitt R Keeffe E Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2A and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis Journal of Hepatology 2009 S385","DOI":"10.1016\/S0168-8278(09)61061-8"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0023|cit23","first-page":"S459","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1: final report","volume":"52","author":"Shiffman","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD009182.pub2-BIB0024|cit24","first-page":"874A","article-title":"Nitazoxanide for the prevention of recurrent hepatitis C virus infection after liver transplantation: A pilot study","volume":"52","author":"Asrani","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Basu P Rayapudi K Shah NJ Krishnaswamy N Pacana T Khemani J Effects of high dose ribavirin (RBV), alinia (nitazoxanide) and pegylated Interferon (peg) alfa-2a in attaining sustained viral response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) - interim results in naive genotype 1 patients Hepatology 2009 730A 1A","DOI":"10.14309\/00000434-200910003-00330"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Basu P Rayapudi K Shah NJ Pacana T Krishnaswamy N Brown R Effect of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated Interferon (pegifn) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C Journal of Hepatology 2010 S102","DOI":"10.1016\/S0168-8278(10)60244-9"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009182.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.14309\/00000434-200910003-00330","article-title":"Effects of high dose ribavirin, alinia (R) (nitazoxanide) and pegylated interferon alfa-2a in attaining sustained viral response in treatment of chronic hepatitis C (ERAIS-C Trial) - interim results in naive genotype 1 patients","volume":"104","author":"Basu","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"S2","key":"10.1002\/14651858.CD009182.pub2-BIB0028|cit28","first-page":"S1","article-title":"Effect of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated interferon (pegIFN) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) in na\u00efve genotype 1 patients","volume":"14","author":"Basu","year":"2010","journal-title":"International Journal of Infectuous Diseases"},{"issue":"5","key":"10.1002\/14651858.CD009182.pub2-BIB0029|cit29","first-page":"S","article-title":"Effects of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated interferon (pegIFN) alfa-2a in attaining sustained virological response (SVR) in treatment of chronic hepatitis C (ERAIS-C trial) in naive genotype 1 patients","volume":"138","author":"Basu","year":"2010","journal-title":"Gastroenteology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Kamal SM Hepatitis C virus genotype 4 therapy: progress and challenges Liver International 2011 45 52","DOI":"10.1111\/j.1478-3231.2010.02385.x"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Kanda T Imazeki F Yokosuka O New antiviral therapies for chronic hepatitis C Hepatology International 2010 548 61","DOI":"10.1007\/s12072-010-9193-3"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Keeffe EB Future treatment of chronic hepatitis C Antiviral Therapy 2007 1015 25","DOI":"10.1177\/135965350701200715"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0033|cit33","first-page":"34","article-title":"Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C. 19th Conference of the Asian Pacific Association for the Study of the Liver, Hong Kong, China","volume":"3","author":"Keeffe","year":"2009","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0034|cit34","unstructured":"Keeffe EB Current research on nitazoxanide in the treatment of chronic hepatitis C Gastroenterology and Hepatology 2009 620 2"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Mederacke I Wedemeyer H Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Annals of Hepatology 2009 166 8","DOI":"10.1016\/S1665-2681(19)31800-9"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0036|cit36","unstructured":"Parfieniuk A Flisiak R New perspectives in treatment of chronic hepatitis C Gastroenterologia Polska 2009 329 32"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0037|cit37","unstructured":"Pockros PJ Emerging therapies for chronic hepatitis C virus Gastroenterology and Hepatology 2008 729 34"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0038|cit38","unstructured":"Pockros PJ Balart LA Advances in hepatology research Reviews in Gastroenterological Disorders 2008 194 212"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0039|cit39","unstructured":"Pockros PJ Emerging therapy for chronic hepatitis C: Highlights from the 59th Annual Meeting of the American Association for the Study of Liver Diseases, 31 October-4 November 2008, San Francisco, CA Reviews in Gastroenterological Disorders 2009 27 34"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Rossignol JF Keeffe EB Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C Future Microbiology 2008 539 45","DOI":"10.2217\/17460913.3.5.539"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Rossignol JF Elfert A Keeffe EB Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (pegifn) plus NTZ for treatment of chronic hepatitis C: final report Hepatology 2008 1132A 1133A","DOI":"10.1016\/S0168-8278(08)60834-X"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Rossignol JF Elfert A Keeffe EB Evaluation of a 4-week lead-in with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C Journal of Clinical Gastroenterology 2010 504 9 10.1097\/MCG.0b013e3181bf9b15","DOI":"10.1097\/MCG.0b013e3181bf9b15"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Rossignol JF Elfert A Keeffe EB Evaluation of a 4-week lead-in with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report Hepatology 2008 1132A 3A","DOI":"10.1016\/S0168-8278(08)60834-X"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009182.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1016\/S0168-8278(09)60974-0","article-title":"Interim results: single center pilot efficacy study of nitazoxanide plus pegylated alpha-2a interferon and ribavirin in prior genotype 1 nonresponders with HCV induced cirrhosis","volume":"50","author":"Yoffe","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"S4","key":"10.1002\/14651858.CD009182.pub2-BIB0045|cit45","first-page":"1034A","article-title":"Pilot study of lead-in nitazoxanide plus pegylated alpha-2a interferon and ribavirin in HCV-genotype 1 nonresponders with cirrhosis: Interim results","volume":"50","author":"Yoffe","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0046|cit46","unstructured":"Kohla M EL-Said H El-Fert AY Ehsan N Ezzat S Taha HA Impact of nitazoxanide on early virologic response (EVR) in Egyptian patients with chronic hepatitis C genotype 4: a double blind placebo-controlled trial Hepatology 2012 583A"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0047|cit47","unstructured":"Kohla M El-Said H El-Fert A Ehsan N Ezzat S Taha H Impact of nitazoxanide on rapid virologic response in patients with chronic hepatitis C genotype 4: a double blind placebo-controlled trial Journal of Gastroenterology and Hepatology 2012 236"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0048|cit48","unstructured":"NCT01197157 Study of the impact of nitazoxanide on chronic hepatitis patients http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01197157?term=NCT01197157&rank=1"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1743-422X-9-57","article-title":"Current status and future directions in the management of chronic hepatitis C","volume":"9","author":"Aman","year":"2012","journal-title":"Virology Journal"},{"issue":"12","key":"10.1002\/14651858.CD009182.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004","volume":"46","author":"Amon","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482.","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009182.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005527.pub2","article-title":"Ribavirin monotherapy for chronic hepatitis C","author":"Brok","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/gut.47.5.610","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma","volume":"47","author":"Bown","year":"2000","journal-title":"Gut"},{"issue":"Suppl E","key":"10.1002\/14651858.CD009182.pub2-BIB0057|cit57","first-page":"156","article-title":"Adverse effects and other safety aspects of the hepatitis C antivirals","volume":"15","author":"Chutaputti","year":"2000","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0058|cit58","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis ctu.dk\/tsa\/"},{"issue":"6B","key":"10.1002\/14651858.CD009182.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/S0002-9343(99)00376-9","article-title":"Hepatitis C virus genotypes and quasi species","volume":"107","author":"Davis","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009182.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods of combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009182.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD009182.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0064|cit64","unstructured":"US Food Drugs Administration Drug development guidelines for Hepatitis C virus http:\/\/www.fda.gov\/drugs\/newsevents\/ucm385395.htm"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0065|cit65","first-page":"229","article-title":"Hepatitis C virus","volume-title":"Liver. A Complete Book on Hepato-Pancreato-Biliary Diseases","author":"Foster","year":"2009"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"975\u201382","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","article-title":"Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection","volume":"55","author":"Fried","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(98)80021-4","article-title":"Quality assessment of reports on clinical trials in the Journal of Hepatology","volume":"29","author":"Gluud","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1478-3231.1999.tb00001.x","article-title":"Evidence based medicine in LIVER","volume":"19","author":"Gluud","year":"1999","journal-title":"Liver"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1053\/gast.2002.32390","article-title":"Validity of randomized clinical trials in Gastroenterology from 1964 to 2000","volume":"122","author":"Kjaergard","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2005.12.006","article-title":"The culture of designing hepato-biliary randomised trials","volume":"44","author":"Gluud","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0074|cit74","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2013, Issue 12. Art. No.: LIVER"},{"issue":"12","key":"10.1002\/14651858.CD009182.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"e83313","DOI":"10.1371\/journal.pone.0083313","article-title":"Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?","volume":"8","author":"Gurusamy","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"346\u201355","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Hauser G Awad T Brok J Thorlund K \u0160timac D Mabrouk M Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Cochrane Database on Systematic Reviews 2014 (to be published) 10.1002\/14651858.CD005441.pub3","DOI":"10.1002\/14651858.CD005441.pub3"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Hauser G Awad T Thorlund K \u0160timac D Mabrouk M Gluud C Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C Cochrane Database of Systematic Reviews 2014 (to be published) 10.1002\/14651858.CD005642.pub3.","DOI":"10.1002\/14651858.CD005642.pub3"},{"issue":"11","key":"10.1002\/14651858.CD009182.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0080|cit80","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0081|cit81","first-page":"http:\/\/otm.oxfo","article-title":"Viral hepatitis - clinical aspects","volume-title":"Oxford Textbook of Medicine","author":"Hodgson","year":"2003"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Edition)"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0083|cit83","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Original article telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.9734\/BJMMR\/2013\/3208","article-title":"The necessity of randomized clinical trials","volume":"3","author":"Jakobsen","year":"2013","journal-title":"British Journal of Medicine and Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0086|cit86","first-page":"251","article-title":"A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4","volume":"41","author":"Kabil","year":"2011","journal-title":"Journal of the Egyptian Society of Parasitology"},{"issue":"11","key":"10.1002\/14651858.CD009182.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009182.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e52158","DOI":"10.1371\/journal.pone.0052158","article-title":"Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis","volume":"7","author":"Kong","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antiviral Research"},{"issue":"Suppl","key":"10.1002\/14651858.CD009182.pub2-BIB0090|cit90","first-page":"356A","article-title":"Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance","volume":"48","author":"Korba","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9883","key":"10.1002\/14651858.CD009182.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"New England Journal of Medicie"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C Infection","volume":"368","author":"Lawitz","year":"May 2013","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009182.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9286","key":"10.1002\/14651858.CD009182.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0097|cit97","first-page":"92\u2013111","article-title":"Current therapies for chronic hepatitis C","volume":"31","author":"McKenzie","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0100|cit100","unstructured":"National Institutes of Health Chronic hepatitis C: current disease management http:\/\/digestive.niddk.nih.gov\/ddiseases\/pubs\/chronichepc\/"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0101|cit101","unstructured":"United Network for Organ Sharing 2005 OPTN\/SRTR Annual Report (Chapter VI ; Liver and Intestine Transplantation in the United States, 1995-2004) http:\/\/optn.transplant.hrsa.gov\/ar2009\/ar_archives.htm"},{"issue":"9","key":"10.1002\/14651858.CD009182.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1046\/j.1365-2036.2001.01066.x","article-title":"Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru","volume":"15","author":"Ortiz","year":"2001","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009182.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1128\/AAC.50.3.1112-1117.2006","article-title":"Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species","volume":"50","author":"Pankuch","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Penin F Dubuisson J Rey FA Moradpour D Pawlotsky J Structural biology of hepatitis C virus Hepatology 2004 5 19 10.1002\/hep.20032","DOI":"10.1002\/hep.20032"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009182.pub2-BIB0106|cit106","first-page":"3708","article-title":"Study and improvement of spectrophotometric and HPLC methods for the determination of nitazoxanide in pharmaceutical preparations","volume":"4","author":"Reddy","year":"2012","journal-title":"Journal of Chemical and Pharmaceutical Research"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0107|cit107","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1006\/jmbi.2001.5055","article-title":"Recent advances in the molecular biology of hepatitis C virus","volume":"313","author":"Rosenberg","year":"2001","journal-title":"Journal of Molecular Biology"},{"issue":"6","key":"10.1002\/14651858.CD009182.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0035-9203(98)90804-5","article-title":"A double-\u2018blind\u2019 placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in aids patients in Mexico","volume":"92","author":"Rossignol","year":"1998","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1086\/321008","article-title":"Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide","volume":"184","author":"Rossignol","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD009182.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/17425250902988487","article-title":"Thiazolides: a new class of antiviral drugs","volume":"5","author":"Rossignol","year":"2009","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"35","key":"10.1002\/14651858.CD009182.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD009182.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD009182.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijsu.2011.09.004","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Internal Journal of Surgery"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Seeff LB Hoofnagle JH National Institutes of Health consensus development conference: Management of hepatitis C: 2002 Hepatology 2002 S1 S2 10.1002\/hep.1840360702","DOI":"10.1053\/jhep.2002.36992"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009182.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clinthera.2012.12.017","article-title":"Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials","volume":"35","author":"Sitole","year":"February 2013","journal-title":"Clinical Therapeutics"},{"issue":"RR04","key":"10.1002\/14651858.CD009182.pub2-BIB0120|cit120","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"Smith","year":"2012","journal-title":"Centers for Disease Control and Prevention"},{"issue":"5","key":"10.1002\/14651858.CD009182.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CPP40213","article-title":"Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses","volume":"40","author":"Stockis","year":"2002","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009182.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"AASLD practice guideline: diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD009182.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0128|cit128","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0129|cit129","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual forTrial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0130|cit130","volume-title":"Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses","author":"Regenmortel","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD009182.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0134|cit134","unstructured":"World Health Organization Viral hepatitis. Report by the secretariat apps.who.int\/gb\/ebwha\/pdf_files\/WHA63\/A63_15-en.pdf"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0135|cit135","unstructured":"World Health Organiziation Hepatitis C. Fact sheet No. 164 http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html 2011"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"6","key":"10.1002\/14651858.CD009182.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2169\/internalmedicine.52.8156","article-title":"The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials","volume":"52","author":"Yang","year":"2013","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD009182.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009182.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:03:44Z","timestamp":1711983824000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009182.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,6]]},"references-count":138,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009182.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,6]]}}}